Adam Castaño, MD MS, is Senior Medical Director for Tafamidis, U.S. Medical Affairs at Pfizer. He is a board certified cardiologist who previously practiced at Columbia University College of Physicians & Surgeons-NewYork Presbyterian Hospital where he was Assistant Professor and Co-Director of the Center for Cardiac Amyloidosis. He also holds specialization in Nuclear Cardiology, Advanced Cardiac Imaging and Echocardiography and has worked as a Critical Care Cardiologist. Dr. Castaño completed his undergraduate degree in Molecular Biology at Princeton University, his medical degree at the University of Michigan, and his residency in Internal Medicine at Columbia University College of Physicians & Surgeons. He stayed on at Columbia to complete his Fellowship in Cardiovascular Medicine and an Advanced Fellowship in Advanced Cardiac Imaging. He has researched and published extensively in the field of cardiac amyloidosis, with multiple manuscripts, textbook chapters, and invitations to speak at national and international conferences. He has a longstanding clinical interest and expertise in cardiac amyloidosis and novel cardiac imaging technologies (nuclear cardiology and echocardiography) to diagnose and monitor disease progression and response to therapy. Dr. Castaño has also conducted translational research at the Columbia University Division of Cardiology, Centers for Advanced Cardiac Care, Intervention Vascular Therapy, and Nuclear Cardiology. He is interested in emerging investigational amyloid therapies for the treatment of patients with TTR cardiac amyloidosis.
General Statement of Disclosure:
SALARY: ACC / Merck Fellowship in Cardiovascular Disease(SIGNIFICANT) OTHER FINANCIAL BENEFIT: Pfizer Inc.(SIGNIFICANT)